|

BNT327 Clinical Trials

6 actively recruiting trials across 5 locations

▼ -1 trial since May 2026

Also known as: PM8002, Pumitamig

Pipeline

Phase 2: 1Phase 1/2: 5

Top Sponsors

  • BioNTech SE5
  • DualityBio Inc.1

Indications

Other1 trial

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
Phase 1/2

Phoenix, Arizona1 trial

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Mayo Clinic Arizona

Phase 1/2

Beverly Hills, California1 trial

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Beverly Hills Cancer Center

Phase 1/2

Los Angeles, California1 trial

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA06-0

Phase 2

Stanford, California1 trial

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Stanford Cancer Institute

Phase 1/2

New Haven, Connecticut1 trial

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

Yale University

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.